Breast Cancer Clinical Trial
Official title:
Bridging the Gap: Incorporating Exercise Evidence Into Clinical Practice in Breast Cancer Care in Ontario
| Verified date | February 2019 |
| Source | Hamilton Health Sciences Corporation |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Breast cancer (BC) and its treatments lead to numerous side effects that affect a person's
life for years after treatment has ended. Research shows that regular exercise limits many of
these side effects. However, less than 30% of BC survivors regularly exercise due to many
barriers that include patients being unaware of the benefits of exercise, health
professionals facing institutional, personal, and patient-related barriers to promoting
exercise, and a lack of knowledge translation (KT) strategies within cancer institutions that
focus on accessible exercise interventions and education by physiotherapists. For this
project, a pilot study is needed as the first step in order to assess process and resource
variables before implementation of a large-scale intervention.
The primary objective of this pilot trial is to assess the feasibility of conducting a larger
trial to evaluate the effects of a novel KT intervention using exercise and self-management
versus usual care among BC survivors. The secondary objective is to determine preliminary
estimates of effects of the KT intervention of exercise plus self-management (SM) program
versus usual care on (a) levels of exercise knowledge and behaviour, (b) health related
quality of life and (c) resource utilization, among BC survivors over a four month period.
| Status | Completed |
| Enrollment | 26 |
| Est. completion date | October 1, 2018 |
| Est. primary completion date | March 1, 2018 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Community-dwelling, English-speaking women, over 18 years, who are currently undergoing chemotherapy for Stage 1-3 BC and have been cleared by their oncologist to participate in moderate intensity aerobic exercise Exclusion Criteria: - Participants will be excluded from the study if they have another chronic disease, cognitive impairment or injury that prevents them from participating independently in moderate intensity exercise |
| Country | Name | City | State |
|---|---|---|---|
| Canada | McMaster University | Hamilton | Ontario |
| Lead Sponsor | Collaborator |
|---|---|
| Hamilton Health Sciences Corporation |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Study Recruitment Rate: percentage of eligible patients recruited | A recruitment log will be kept, detailing reasons for non-participation. | Baseline | |
| Primary | Intervention Retention Rate: percentage of consented participants who completed the intervention | Attendance will be tracked on the feasibility data collection sheet and reasons for non-participation on scheduled intervention days will be documented using an adherence log | Post-intervention (2 months post baseline) | |
| Primary | Intervention Adherence Rate: percentage of total intervention sessions attended | Attendance will be tracked on the feasibility data collection sheet and reasons for non-participation on scheduled intervention days will be documented using an adherence log | Post-intervention (2 months post baseline) | |
| Secondary | Health related quality of life | Functional Assessment of Cancer Therapy-Breast | Baseline, post intervention (2 months post baseline), 2 and 4 month follow up (post intervention completion) | |
| Secondary | Exercise knowledge | Theory of planned behaviour questionnaire | Baseline, post intervention (2 months post baseline), 2 and 4 month follow up (post intervention completion) | |
| Secondary | Exercise behaviour | Theory of planned behaviour questionnaire | Baseline, post intervention (2 months post baseline), 2 and 4 month follow up (post intervention completion) | |
| Secondary | Health status | European Quality of Life-Five Dimension (EQ-5D) | Baseline, post intervention (2 months post baseline), 2 and 4 month follow up (post intervention completion) | |
| Secondary | Use of health care services | Piloted form assessing doctor visits, procedures, medication use, missed days of work | Baseline, post intervention (2 months post baseline), 2 and 4 month follow up (post intervention completion) | |
| Secondary | Physical Activity Level | Godin Leisure Time Physical Activity Questionnaire | Baseline, post intervention, 2 and 4 month follow up |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |